EUVIMEDEUVIMED entdecken
Open Access

Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer’s disease in mice

Zhengjiang Qian, Bowei Li, Xin Meng, Jianming Liao, Guangxing Wang, Yanjiao Li, Qian Luo, Keqiang Ye iD

Neuropsychopharmacology · 2024

DOI: 10.1038/s41386-023-01774-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropsychopharmacology, 2024. Verfasst von Zhengjiang Qian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life and Health Sciences, Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology (SIAT), Chinese A…. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases, Cysteine Endopeptidases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a progressive neurodegenerative disease with cognitive dysfunction as its major clinical symptom. However, there is no disease-modifying small molecular medicine to effectively slow down progression of the disease. Here, we show an optimized asparagine endopeptidase (AEP, also known as δ-secretase) inhibitor, #11 A, that displays an orderly in vivo pharmacokinetics/pharmacodynamics (PK/PD) relationship and robustly attenuates AD pathologies in a sporadic AD mouse model. #11 A is brain permeable with great oral bioavailability. It blocks AEP cleavage of APP and Tau dose-dependently, and significantly decreases Aβ40 and Aβ42 and p-Tau levels in APP/PS1 and Tau P301S mice after oral administration. Notably, #11 A strongly inhibits AEP and prevents mouse APP and Tau fragmentation by AEP, leading to reduction of mouse Aβ42 (mAβ42), mAβ40 and mouse p-Tau181 levels in Thy1-ApoE4/C/EBPβ transgenic mice in a dose-dependent manner. Repeated oral administration of #11 A substantially decreases mAβ aggregation as validated by Aβ PET assay, Tau pathology, neurodegeneration and brain volume reduction, resulting in alleviation of cognitive impairment. Therefore, our results support that #11 A is a disease-modifying preclinical candidate for pharmacologically treating AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNeurodegenerative DiseasesCysteine EndopeptidasesMiceAnimalstau ProteinsMice, TransgenicAmyloid beta-PeptidesDisease Models, AnimalAsparaginyl Endopeptidase

Substanzen

tau ProteinsAmyloid beta-PeptidesCysteine EndopeptidasesAsparaginyl Endopeptidase

Autor:innen und Institutionen

  • Faculty of Life and Health Sciences, Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, 518055, Guangdong, China.
  • Shenzhen Institute of Advanced Technology, University of Chinese Academy of Science, Shenzhen, Guangdong, 518055, China.
  • Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
  • School of Medicine, Tongji University, Shanghai, 200092, China.
  • Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China. qian.luo@siat.ac.cn.
  • Faculty of Life and Health Sciences, Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, 518055, Guangdong, China. kq.ye@siat.ac.…

ORCID-Profile: Keqiang Ye

Zitieren

APA

Qian, Z., Li, B., Meng, X., Liao, J., Wang, G., Li, Y., Luo, Q., & Ye, K. (2024). Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer’s disease in mice. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01774-2

Vancouver

Qian Z, Li B, Meng X, Liao J, Wang G, Li Y, et al. Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer’s disease in mice. Neuropsychopharmacology. 2024. doi:10.1038/s41386-023-01774-2

BibTeX
@article{Qian2024,
  author = {Qian, Zhengjiang and Li, Bowei and Meng, Xin and Liao, Jianming and Wang, Guangxing and Li, Yanjiao and Luo, Qian and Ye, Keqiang},
  title = {Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer’s disease in mice},
  journal = {Neuropsychopharmacology},
  year = {2024},
  doi = {10.1038/s41386-023-01774-2}
}
Kostenlos starten →